Paula
Rodríguez Otero

2024

1. A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies

   British Journal of Haematology

2. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

   Haematologica

3. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

4. CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?

   Hemato, Vol. 5, Núm. 2, pp. 171-179

5. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

6. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

7. Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)

   Blood Cancer Journal

8. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

9. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

   New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

10. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

    Blood Cancer Journal, Vol. 14, Núm. 1

11. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

12. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

13. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

14. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

15. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

16. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

17. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

18. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast

    Advances in Therapy

19. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

20. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355